| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
University Department of Medicine, Manchester Royal Infirmary, (E.B.M., M.D., P.E.S.), Manchester; and the Department of Clinical Biochemistry, St. Bartholomews and the Royal London School of Medicine and Dentistry (H.L.J.M., N.J.S.), London, United Kingdom; the Department of Biochemistry, Queens University (G.J., V.B.), Kingston, Ontario, Canada; and Bone Care International (C.W.B., J.C.K.), Madison, Wisconsin 53713
Address all correspondence and requests for reprints to: Prof. E. B. Mawer, Department of Medicine, Manchester Royal Infirmary, Manchester, United Kingdom M13 9WL.
We have produced evidence for a new metabolic pathway for vitamin D2 in humans involving the production of 24-hydroxyvitamin D2 (24OHD2) and 1,24-dihydroxyvitamin D2 [1,24-(OH)2D2]. These metabolites were produced after either a single large dose (106 IU) of vitamin D2 or repeated daily doses between 103 and 5 x 104 IU. We developed assay systems for the metabolites in human serum and showed that in some chronically treated patients, the concentration of 1,24-(OH)2D2 equalled that of 1,25-(OH)2D2 at about 100 pmol/L. The metabolites were identified by high performance liquid chromatography with diode array spectrophotometry for 24OHD2 and by high resolution gas chromatography-mass spectrometry for 1,24-(OH)2D2. We show that 1,24-(OH)2D2 synthesis can be stimulated by PTH, indicating a renal origin for this metabolite and postulate that it is formed from 24OHD2, which may be synthesized in liver. We conclude from this study that vitamin D2 gives rise to two biologically active products, 1,24-(OH)2D2 and 1,25-(OH)2D2, and that 1,24-(OH)2D2 could be an attractive naturally occurring analog of 1,25-(OH)2D3 for clinical use.
This article has been cited by other articles:
![]() |
K. J. Martin and E. A. Gonzalez Metabolic Bone Disease in Chronic Kidney Disease J. Am. Soc. Nephrol., March 1, 2007; 18(3): 875 - 885. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A Houghton and R. Vieth The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am. J. Clinical Nutrition, October 1, 2006; 84(4): 694 - 697. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Maunsell, D. J. Wright, and S. J. Rainbow Routine Isotope-Dilution Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Measurement of the 25-Hydroxy Metabolites of Vitamins D2 and D3 Clin. Chem., September 1, 2005; 51(9): 1683 - 1690. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Gupta, Y. A. He, K. S. Patrick, J. R. Halpert, and N. H. Bell CYP3A4 Is a Vitamin D-24- and 25-Hydroxylase: Analysis of Structure Function by Site-Directed Mutagenesis J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1210 - 1219. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Upton, J. C. Knutson, C. W. Bishop, and L. W. LeVan Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone Nephrol. Dial. Transplant., April 1, 2003; 18(4): 750 - 758. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Vieth, P.-C. R Chan, and G. D MacFarlane Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level Am. J. Clinical Nutrition, February 1, 2001; 73(2): 288 - 294. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Schroeder and J. Cunningham What's new in vitamin D for the nephrologist? Nephrol. Dial. Transplant., April 1, 2000; 15(4): 460 - 466. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |